Practical guide for prescribing MAOIs: Debunking myths and removing barriers

CNS Spectrums

Volumn 17, Issue 1, 2012, Pages 2-10

  Grady, Meghan M ^a   Stahl, Stephen M ^a,b,c  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Depression; Interaction; MAOI; Monoamine oxidase

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOMIPRAMINE; CODEINE; CYCLOBENZAPRINE; DECONGESTIVE AGENT; MIVACURIUM; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OXCARBAZEPINE; PARACETAMOL; PETHIDINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; RAPACURONIUM BROMIDE; SELEGILINE; SEROTONIN AGONIST; SEROTONIN TRANSPORTER; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG;

AGITATION; ARTICLE; BRAIN DAMAGE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMA; COMMON COLD; CONFUSION; DEPRESSION; DIET RESTRICTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FIRST PASS EFFECT; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERTHERMIA; LOW DRUG DOSE; MIGRAINE; MYOCLONUS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE; SEROTONIN RELEASE; SEROTONIN SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

ANXIETY DISORDERS; DEPRESSION; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HUMANS; MONOAMINE OXIDASE INHIBITORS;

EID: 84869235839     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291200003X     Document Type: Article

References (46)

1. Zisook S. A clinical overview of monoamine oxidase inhibitors. Psychosomatics. 1985; 26(3): 240-246, 251.
2. Tollefson GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry. 1983; 44(8): 280-288.
3. Versiani M, Nardi AE, Mundim FD, et al. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol. 1996; 11(suppl 3): 83-88.
4. Cole JO, Bodkin JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Current Psychiatry. 2002; 1(6): 40-47.
5. Magyar MK, Szatmary I, Szebeni G, Lengyel J. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J Neural Transm Suppl. 2007; (72): 165-173.
6. Stahl SM. Stahl's Essential Psychopharmacology, 3rd ed. New York, NY: Cambridge University Press; 2008.
7. McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry. 1982; 43(5): 178-181.
8. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleveland Clinic J Med. 2010; 77(12): 859-882.
9. Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996; 57(3): 99-104.
10. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988; 26: 31-56.
11. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989; 9(6): 397-402.
12. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999; 60(3): 191-193.
13. Shulman KI, Walker SE. A reevaluation of dietary restrictions for irreversible monoamine oxidase inhibitors. Psychiatr Ann. 2001; 31(6): 378-384.
14. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995; 15(4 suppl 2): 16S-23S.
15. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003; 64(2): 208-214.
16. Robinson DS. Transdermal selegiline: a new-generation MAOI. Primary Psychiatry. 2006; 13(5): 33-35.
17. Zsilla G, Foldi P, Held G, Szekely AM, Knoll J. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission: comparison with clorgyline. Pol J Pharmacol Pharm. 1986; 38(1): 57-67.
18. Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. Biol Chem. 2004; 279(38): 39645-39652.
19. Mendis N, Pare CM, Sandler M, Glover V, Stern GM. Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology. 1981; 73(1): 87-90.
20. Mann JJ, Frances A, Kaplan RD, Kocsis J, Peselow ED, Gershon S. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol. 1982; 2(1): 54-57.
21. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry. 2007; 68(suppl 8): 4246.
22. Wecker L, Copeland JS, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003; 54(10): 1099-541104.
23. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003; 55(1): 27-34.
24. Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006; 67(9): 1354-1361.
25. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007; 68(suppl 8): 35-41.
26. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007; 68(suppl 8): 26-34.
27. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Pharmacol Exp Ther. 1989; 248(1): 400-414.
28. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999; 20(3): 226-247.
29. Sternbach H. Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Current Psychiatry. 2003; 2(5): 15-23.
30. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006; 59(11): 1046-1051.
31. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006; 42(11): 1578-1583.
32. Dvir Y, Smallwood P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry. 2008; 30(3): 284-287.
33. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151(6): 737-748.
34. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008; 7(5): 587-596.
35. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148(6): 705-713.
36. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med. 2003; 96(9): 635-642.
37. Azzaro AJ, VanDenBerg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. J Clin Pharmacol. 2007; 47(8): 978-990.
38. Stahl SM. Essential Psychopharmacology: The Prescribers Guide, 4th ed. New York, NY: Cambridge University Press; 2011.
39. Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004; 65(11): 1520-1524.
40. Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry. 1985; 46(6): 206-209.
41. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991; 11(2): 127-132.
42. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995; 34(3): 187-192.
43. Huyse FJ, Touw DJ, van Schijndel RS, de Lange JJ, Slaets JP. Psychotropic drugs and the perioperative period: a proprosal for a guideline in elective surgery. Psychosomatics. 2006; 47(1): 8-22.
44. Fuller RW, Snoddy HD. Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors. Toxicol Appl Pharmacol. 1975; 32(1): 129-134.
45. Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011; 25(5): 359-370.
46. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005; 95(4): 434-441.